Anti-CD20s Linked to Higher COVID-19 Severity in MS medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Disability and age were associated with poorer COVID-19 outcomes in multiple sclerosis (MS) patients, registry data showed.
Of approximately 2,000 people with MS and COVID-19 in North America, 17.8% of non-ambulatory patients died, compared with 4.3% of MS patients who walked with assistance and 0.6% of patients who were fully ambulatory, reported Amber Salter, PhD, of Washington University School of Medicine in St. Louis. Death occured most frequently in MS patients, ages 75 and older, who had COVID-19, she said in a presentation at ACTRIMS Forum 2021, the annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis.
Findings came from COViMS, a registry supported by the Consortium of MS Centers, the National MS Society, and the MS Society of Canada. Healthcare professionals were asked to report patients with MS and other related diseases after a minimum of 7 days and sufficient time had passed to observe the COVID-19 disease course, Salter said.
E-Mail
IMAGE: Dr. Dobryakova is research scientist in the Center for Traumatic Brain Injury Research at Kessler Foundation. view more
Credit: Kessler Foundation
East Hanover, NJ, December 10, 2020. Researchers at Montclair State University and Kessler Foundation have received funding totaling $651,997 from the National Multiple Sclerosis Society to measure memory-related abilities in individuals with and without multiple sclerosis (MS) for clues to how such cognitive processes are altered by MS. Joshua Sandry, PhD, assistant professor of psychology at Montclair State and Ekaterina Dobryakova, PhD, research scientist in the Center for Traumatic Brain Injury Research at Kessler Foundation, collaborate on the 4-year study, titled Neuroimaging of Hippocampally Mediated Memory Dysfunction in Multiple Sclerosis.